中国药学杂志 Chinese Pharmaceutical Journal
ISSN 1001-2494 CN 11-2162/R

中国药学杂志 » 2013, Vol. 48 » Issue (3) :161-164 DOI: 10.11669/cpj.2013.03.001

适体介导的药物靶向递释系统的研究进展

张弛，张奇志

复旦大学药学院，上海 201203

摘要 目的 综述适体(aptamers)在介导药物靶向递送方面的研究进展。 方法 查阅近年来国内外相关文献，对适体的产生及特点进行阐述，并整理、分析和归纳其在药物靶向递送系统中的应用。 结果与结论 适体是一类能与许多生物大分子或细胞特异性结合的核酸分子，能够介导药物或载体到达特定的器官、组织甚至细胞，从而提高药物在靶组织/靶细胞的浓度，为药物靶向递送系统的研究提供了新的思路和方向。

关键词： 适体 靶向递送系统 特异性

Abstract：

Keywords：

收稿日期: 2013-02-04;

通讯作者 张奇志 Email: qzzhang70@yahoo.com.cn

作者简介: 张弛，女，硕士研究生 研究方向：递药系统的脑靶向性 通讯作者：张奇志，女，副教授，硕士生导师 研究方向：递药系统的脑靶向性和鼻腔新制剂 Tel：(021)51980068，Fax：(021)51980067 E-mail：qzzhang70@yahoo.com.cn

引用本文:

张弛, 张奇志 .适体介导的药物靶向递释系统的研究进展[J] 中国药学杂志, 2013,V48(3): 161-164

ZHANG Chi, ZHANG Qi-Zhi .[J] Chinese Pharmaceutical Journal, 2013,V48(3): 161-164

[1] YANG L, ZHANG X, YE M, *et al*. Aptamer-conjugated nanomaterials and their applications. *Adv Drug Deliv Rev*, 2011, 63(14-15): 1361-1370.

[2] PROSKE D, BLANK M, BUHMANN R, *et al*. Aptamers-basic research, drug development, and clinical applications. *Appl Microbiol Biotechnol*, 2005, 69(4): 367-374.

[3] ELLINGTON A D, SZOSTAK J W. *In vitro* selection of RNA molecules that bind specific ligands. *Nature*, 1990, 346(6287): 818-822.

[4] TUERK C, GOLD L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science*, 1990, 249(4968): 505-510.

[5] BUNKA D H, STOCKLEY P G. Aptamers come of age - at last. *Nat Rev Microbiol*, 2006, 4(8): 588-596.

[6] SHANGGUAN D, LI Y, TANG Z, *et al*. Aptamers evolved from live cells as effective molecular probes for cancer study. *Proc Natl Acad Sci USA*, 2006, 103(32): 11838-11843.

[7] GUTSAEVA D R, PARKERSON J B, YERIGENAHALLY S D, *et al*. Inhibition of cell adhesion by anti-P-selectin aptamer: A new potential therapeutic agent for sickle cell disease. *Blood*, 2011, 117(2): 727-735.

[8] HUANG Y F, SEFAH K, BAMRUNGSAP S, *et al*. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. *Langmuir*, 2008, 24(20): 11860-11865.

[9] YANG C X, GE Z Q.Research and development of aptamers acting as drug targeting carriers. *Chin Med Biotechnol*(中国医药生物技术), 2010, 5(4): 297-299.

[10] YANG L, ZHANG X, YE M, *et al*. Aptamer-conjugated nanomaterials and their applications. *Adv Drug Deliv Rev*, 2011, 63(14-15): 1361-1370.

[11] TAN W, WANG H, CHEN Y, *et al*. Molecular aptamers for drug delivery. *Trends Biotechnol*, 2011, 29(12): 634-640.

[12] ZHANG Y, CHEN Y, HAN D, *et al*. Aptamers selected by cell-SELEX for application in cancer studies. *Bioanalysis*, 2010, 2(5): 907-918.

[13] JAYASENA S D. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. *Clin Chem*, 1999, 45(9): 1628-1650.

[14] GROUP E S. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. *Ophthalmology*, 2003, 110(5): 979-986.

[15] RUCKMAN J, GREEN L S, BEESON J, *et al*. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. *J Biol Chem*, 1998, 273(32): 20556-20567.

[16] DOGGRELL S A. Pegaptanib: The first antiangiogenic agent approved for neovascular macular degeneration. *Expert Opin Pharmacother*, 2005, 6(8): 1421-1423.

[17] MONGELARD F, BOUVET P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. *Curr Opin Mol Ther*, 2010, 12(1): 107-114.

[18] KEEFE A D, PAI S, ELLINGTON A. Aptamers as therapeutics. *Nat Rev Drug Discov*, 2010, 9(7): 537-550.

[19] BOUCHARD P R, HUTABARAT R M, THOMPSON K M. Discovery and development of therapeutic aptamers. *Annu Rev Pharmacol Toxicol*, 2010, 50: 237-257.

[20] EULBERG D, KLUSSMANN S. Spiegelmers: Biostable aptamers. *Chembiochem*, 2003, 4(10): 979-983.

[21] FAMULOK M, MAYER G, BLIND M. Nucleic acid aptamers-from selection *in vitro* to applications *in vivo*. *Acc Chem Res*, 2000, 33(9): 591-599.

[22] CHEN X C, DENG Y L, LIN Y, *et al*. Quantum dot-labeled aptamer nanoprobes specifically targeting glioma cells. *Nanotechnology*, 2008, 19(23): 235105.

[23] KO H Y, CHOI K J, LEE C H, *et al*. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin alphavbeta 3 and tenascin-C proteins. *Biomaterials*, 2011, 32(4): 1130-1138.

[24] SUN Z, WANG Y, WEI Y, *et al*. Ag cluster-aptamer hybrid: Specifically marking the nucleus of live cells. *Chem Commun (Camb)*, 2011, 47(43): 11960-11962.

[25] ZUO J M, LI B Q. Nanostructure evolution during cluster growth: Ag on H-terminated Si(111) surfaces. *Phys Rev Lett*, 2002, 88(25 Pt 1): 255502.

[26] HUANG Y F, SHANGGUAN D, LIU H, *et al*. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. *Chembiochem*, 2009, 10(5): 862-868.

[27] CHU T C, MARKS J R, LAVERY L A, *et al*. Aptamer: Toxin conjugates that specifically target prostate tumor cells. *Cancer Res*, 2006, 66(12): 5989-5992.

[28] MEYER C, EYDELER K, MAGBANUA E, *et al*. Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells. *RNA Biol*, 2012, 9(1): 67-80.

[29] TAN W, WANG H, CHEN Y, *et al*. Molecular aptamers for drug delivery. *Trends Biotechnol*, 2011, 29(12): 634-640.

[30] ZHOU J, LI H, LI S, *et al*. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. *Mol Ther*, 2008, 16(8): 1481-1489.

[31] WULLNER U, NEEF I, ELLER A, *et al*. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. *Curr Cancer Drug Targets*, 2008, 8(7): 554-565.

[32] MCNAMARA J N, ANDRECHEK E R, WANG Y, *et al*. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. *Nat Biotechnol*, 2006, 24(8): 1005-1015.

[33] CAO Z, TONG R, MISHRA A, *et al*. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. *Angew Chem Int Ed Engl*, 2009, 48(35): 6494-6498.

[34] MANN A P, BHAVANE R C, SOMASUNDERAM A, *et al*. Thioaptamer conjugated liposomes for tumor vasculature targeting. *Oncotarget*, 2011, 2(4): 298-304.

[35] KATAOKA K, HARADA A, NAGASAKI Y. Block copolymer micelles for drug delivery: Design, characterization and biological significance. *Adv Drug Deliv Rev*, 2001, 47(1): 113-131.

[36] WU Y， SEFAH K， LIU H，*et al*. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. *Proc Natl Acad Sci USA*， 2010， 107(1)： 5-10.

[37] PING S， LAI C. AS1411 Aptamer-conjudated polymeric micelle for targetable cancer therapy. *NSTI-Nanotech*， 2010，(3)： 330-333.

[38] MATHEW A， ARAVIND A， BRAHATHEESWARAN D，*et al*. Amyloid-binding aptamer conjugated curcumin-PLGA aanoparticle for potential use in alzheimer′s disease. *Bio Nano Sci*， 2012，2（2）：83-93.

[39] GUO J， GAO X， SU L，*et al*. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. *Biomaterials*， 2011， 32(31)： 8010-8120.

[40] GAO H， QIAN J， CAO S，*et al*. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. *Biomaterials*， 2012， 33(20)： 5115-5123.

[41] ZHOU J， ROSSI J J. Cell-specific aptamer-mediated targeted drug delivery. *Oligonucleotides*， 2011， 21(1)： 1-10.

[42] VAN DEN BOSSCHE J， AL-JAMAL W T， TIAN B，*et al*. Efficient receptor-independent intracellular translocation of aptamers mediated by conjugation to carbon nanotubes. *Chem Commun (Camb)*， 2010， 46(39)： 7379-7381.

[43] KANG H， TRONDOLI A C， ZHU G，*et al*. Near-infrared light-responsive core-shell nanogels for targeted drug delivery. *ACS Nano*， 2011， 5(6)： 5094-5099.

[1] 谷玉娟，张丽华，傅桂莲.鹿茸线粒体DNA的指纹鉴定研究[J]. 中国药学杂志, 2013,48(3): 170-173

[2] 杜小莉.环氧化酶-2特异性抑制剂——艾瑞昔布[J]. 中国药学杂志, 2012,47(5): 399-

[3] 刘桐辉 王锦 李明成 张丽华 王淼.中药材龟甲细胞色素b基因特异性鉴定研究[J]. 中国药学杂志, 2012,47(3): 182-

[4] 谭莹 张丽华 李明成 王冰梅.中药材川贝母DNA指纹鉴定研究[J]. 中国药学杂志, 2011,46(1): 14-16

[5] 唐晓晶;冯成强;黄璐琦;钱忠直;崔光红;张继.高特异性PCR方法鉴别乌梢蛇及其混淆品[J]. 中国药学杂志, 2007,42(05): 333-336

[6] 张申;江兴林;卫涛涛.银杏叶提取物对H_2O_2诱导的巨噬细胞凋亡的抑制作用[J]. 中国药学杂志, 2006,41(10): 750-753

[7] 孔维佳;张松;韩月臣;张丹;王彦君.5-杂氮-2’-脱氧胞苷抑制人喉癌细胞生长机制的研究[J]. 中国药学杂志, 2006,41(01): 25-28

[8] 祝丹;.非甾体抗炎药物的进展[J]. 中国药学杂志, 2002,22(06): 369-370

[9] 夏东亚;赵庆春;邢春景;伍秋生;向军;刘龙.特异性荧光偏振免疫法监测肾移植后环孢素A全血浓度2013例次[J]. 中国药学杂志, 1998,33(01): 36-38

[10] 张凤春;胡奇芬;仲伯华.免疫毒素的非特异性毒性及其去除[J]. 中国药学杂志, 1996,31(02): 70-73

[11] 张子健.激肽释放酶的检测及其生理效应[J]. 中国药学杂志, 1994,29(04): 195-198